Antiagregačná liečba v kardiológii: súčasný stav a budúce perspektívy / Antiplatelet therapy in cardiology: Current status and future perspectives
Cardiology Letters · 10.11.2026 · 35 (4) · 240-253
DOI: 10.4149/cardiol_2026_4_5_7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiology Letters, online erschienen am 10.11.2026. Verfasst von Juraj Sokol und 7 weiteren Autor:innen.
Abstract (Originalsprache)
Antiplatelet therapy represents one of the cornerstones of the prevention and treatment of atherothrombotic cardiovascular events.However, its contemporary role is progressively shifting from uniform treatment regimens towards an individualized approach based on balancing ischaemic and bleeding risks.This review summarizes the mechanisms of platelet activation and aggregation and the mechanisms of action of the major classes of antiplatelet agents, with particular emphasis on aspirin and P2Y12 receptor inhibitors.Special attention is given to the current role of antiplatelet therapy in primary prevention, where routine aspirin administration is no longer recommended and its use should be restricted to carefully selected patients.In secondary prevention, the article discusses practical treatment strategies for chronic and acute coronary syndromes, including the selection of antiplatelet agents, optimal duration of dual antiplatelet therapy, and strategies for its shortening, de-escalation, or extension.A separate focus is placed on patients requiring concomitant oral anticoagulation and on specific populations, particularly older patients and those with chronic kidney disease, diabetes mellitus, or extremes of body weight.Finally, the review outlines future perspectives in treatment personalization through platelet function testing and pharmacogenetics, as well as emerging therapeutic targets aimed at selectively suppressing pathological thrombosis while preserving physiological haemostasis.Contemporary antiplatelet therapy is therefore evolving from maximal platelet inhibition towards optimization of the balance between prevention of ischaemic events and bleeding risk.Fig. 2, Tab. 3, Ref. 39, on-line full text (Free, PDF), www.cardiologyletters.sk
Zitieren
APA
Sokol, J., Nehaj, F., Hlivák, P., Svetlošák, M., Lisá, L., Lineková, Ľ., Jusko, R., & Plameňová, I. (2026). Antiagregačná liečba v kardiológii: súčasný stav a budúce perspektívy / Antiplatelet therapy in cardiology: Current status and future perspectives. Cardiology Letters, 35(4), 240-253. https://doi.org/10.4149/cardiol_2026_4_5_7
Vancouver
Sokol J, Nehaj F, Hlivák P, Svetlošák M, Lisá L, Lineková Ľ, et al. Antiagregačná liečba v kardiológii: súčasný stav a budúce perspektívy / Antiplatelet therapy in cardiology: Current status and future perspectives. Cardiology Letters. 2026;35(4):240-253. doi:10.4149/cardiol_2026_4_5_7
BibTeX
@article{Sokol2026,
author = {Sokol, Juraj and Nehaj, František and Hlivák, Peter and Svetlošák, Martin and Lisá, Lenka and Lineková, Ľudmila and Jusko, Richard and Plameňová, Ivana},
title = {Antiagregačná liečba v kardiológii: súčasný stav a budúce perspektívy / Antiplatelet therapy in cardiology: Current status and future perspectives},
journal = {Cardiology Letters},
year = {2026},
volume = {35},
number = {4},
pages = {240--253},
doi = {10.4149/cardiol_2026_4_5_7}
}
EUVIMED